Drugs / Isoquercetin
Isoquercetin
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01722669 | May 2012 → Dec 2019 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02446795 | Nov 2016 → Dec 2017 | renal cell carcinoma | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT07303894 | Jan 2026 → Jan 2032 expected | malignant epithelial tumor of ovary, ovarian serous tumor | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04536090 | Jan → Dec 2022 | COVID-19 | Montreal Clinical Research Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT04733651 | Feb → May 2021 | COVID-19 | Nepal Health Research Council | Unknown | No outcome recorded |
| Phase 2 | NCT04474626 | Dec 2020 → Dec 2022 | sickle cell disease, sickle cell-beta zero-thalassemia | Jeffrey Zwicker, MD | Withdrawn | No outcome recorded |
| Phase 2 | NCT04514510 | Nov 2020 → Jun 2022 | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 2 | NCT04622865 | Jun 2020 → Dec 2023 | COVID-19 | AB Science | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02195232 | Jan 2015 → Dec 2018 | venous thromboembolism | Jeffrey Zwicker, MD | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02866448 | Aug → Oct 2016 | cardiovascular disorder | University of Reading | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-08 | AB Science | Results Positive results of the Phase 2 study evaluating masitinib in Covid-19 ab-science.com ↗
The study showed an odds ratio of 2.4 in favor of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. |
| 2020-05-06 | AB Science | Regulatory Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19 ab-science.com ↗
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19 |
All press releases naming this drug 4 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isoquercetin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02446795 ↗ |
| Known as | 3-glucosylquercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Contigoside b | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Glucosyl-3-quercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Hirsutrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | NSC-115918 | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3-d-glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3-o-glucopyranoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3-o-glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin 3.beta.-glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin glucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Quercetin-3-glucose | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | quercetin-3-O-beta-D-glucoside | “Isoquercetin (quercetin-3-O-beta-D-glucoside, also referred to as isoquercitrin) is a naturally occurring monoglucoside of the most studied and widely consumed bioflavonoid, quercetin.” NCT04514510 ↗ |
| Known as | Quercetol 3-monoglucoside | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Known as | Ronacare isoquercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL250450 ↗ |
| Action | Inhibit | “glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and thrombus formation in animal models” PMID 28097231 ↗ Jan 2017 |
| Modality | Small molecule | “glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and thrombus formation in animal models” PMID 28097231 ↗ Jan 2017 |
| Route | Oral | “Following oral administration of 1,000 mg isoquercetin to healthy adults” PMID 28097231 ↗ Jan 2017 |